tetano
Editor, Senior Moderator
Vaccine
In Press, Uncorrected Proof - Note to users
doi:10.1016/j.vaccine.2011.10.034 | How to Cite or Link Using DOI
Permissions & Reprints
Non-adjuvanted 2009 influenza A (H1N1)v vaccine in pregnant women: The results of a French prospective descriptive study
E. Omona, b, C. Damase-Michela, Corresponding Author Contact Information, E-mail The Corresponding Author, C. Hurault-Delaruea, I. Lacroixa, J.L. Montastruca, S. Oustricb, B. Escourroub
a Laboratoire de Pharmacologie M?dicale et Clinique,, Facult? de M?decine, INSERM U1027, Universit? de Toulouse, 37 all?es Jules Guesde, 31 000 Toulouse, France
b D?partement Universitaire de M?decine G?n?rale, Universit? de Toulouse, Facult? de M?decine, France
Received 3 August 2011; revised 12 October 2011; Accepted 13 October 2011. Available online 25 October 2011.
Abstract
In 2009, during the influenza A (H1N1)v pandemic, the French Health authorities recommended influenza immunisation for pregnant women because of the higher risk of serious influenza outcomes in that population. Thus, the non-adjuvanted inactivated influenza vaccine Panenza? was administered to Frenchwomen from the second trimester of pregnancy. Several studies suggest that inactivated seasonal influenza vaccines are safe during pregnancy but there are few data about the effects of new A (H1N1)vaccines (new antigen) on pregnant women.
Objective
The aim of the present prospective study was to describe pregnancy outcomes among women vaccinated with non-adjuvanted influenza vaccines in South Western France.
Methods
the study ran from November 2009 to February 2010 and included, on a voluntary basis, pregnant women who were vaccinated against A (H1N1) influenza in vaccination clinics or maternity wards.
Results
569 pregnant women were monitored until delivery. Compared with the general population, the risks of maternal conditions, malformations and neonatal conditions were not statistically different.
Conclusion
This study does not reveal any sign of safety concerns regarding the effects of the vaccine on pregnancy outcomes.
Highlights
► We describe pregnancy outcomes among French women vaccinated with influenza vaccine. ► Compared with the general population, the risks of maternal conditions were not different. ► Malformation rate and neonatal conditions were also similar. ► No sign of safety concerns regarding A (H1N1)v vaccine in pregnancy has been revealed.
http://www.sciencedirect.com/science/article/pii/S0264410X11016410
In Press, Uncorrected Proof - Note to users
doi:10.1016/j.vaccine.2011.10.034 | How to Cite or Link Using DOI
Permissions & Reprints
Non-adjuvanted 2009 influenza A (H1N1)v vaccine in pregnant women: The results of a French prospective descriptive study
E. Omona, b, C. Damase-Michela, Corresponding Author Contact Information, E-mail The Corresponding Author, C. Hurault-Delaruea, I. Lacroixa, J.L. Montastruca, S. Oustricb, B. Escourroub
a Laboratoire de Pharmacologie M?dicale et Clinique,, Facult? de M?decine, INSERM U1027, Universit? de Toulouse, 37 all?es Jules Guesde, 31 000 Toulouse, France
b D?partement Universitaire de M?decine G?n?rale, Universit? de Toulouse, Facult? de M?decine, France
Received 3 August 2011; revised 12 October 2011; Accepted 13 October 2011. Available online 25 October 2011.
Abstract
In 2009, during the influenza A (H1N1)v pandemic, the French Health authorities recommended influenza immunisation for pregnant women because of the higher risk of serious influenza outcomes in that population. Thus, the non-adjuvanted inactivated influenza vaccine Panenza? was administered to Frenchwomen from the second trimester of pregnancy. Several studies suggest that inactivated seasonal influenza vaccines are safe during pregnancy but there are few data about the effects of new A (H1N1)vaccines (new antigen) on pregnant women.
Objective
The aim of the present prospective study was to describe pregnancy outcomes among women vaccinated with non-adjuvanted influenza vaccines in South Western France.
Methods
the study ran from November 2009 to February 2010 and included, on a voluntary basis, pregnant women who were vaccinated against A (H1N1) influenza in vaccination clinics or maternity wards.
Results
569 pregnant women were monitored until delivery. Compared with the general population, the risks of maternal conditions, malformations and neonatal conditions were not statistically different.
Conclusion
This study does not reveal any sign of safety concerns regarding the effects of the vaccine on pregnancy outcomes.
Highlights
► We describe pregnancy outcomes among French women vaccinated with influenza vaccine. ► Compared with the general population, the risks of maternal conditions were not different. ► Malformation rate and neonatal conditions were also similar. ► No sign of safety concerns regarding A (H1N1)v vaccine in pregnancy has been revealed.
http://www.sciencedirect.com/science/article/pii/S0264410X11016410